To determine the potential of replication-competent (E3-deleted) bovine adenovirus-3 (BAV-3) as a delivery system for vaccine antigens in calves, we evaluated the ability of recombinant BAV-3 expressing different forms of of bovine herpesvirus-1 (BHV-1) glycoprotein gD to protect against BHV-1 infection in calves that had pre-existing BAV-3 specific antibodies. Three- to four-month-old calves, vaccinated intranasally with recombinant BAV-3 expressing full-length gD (BAV3.E3gD) or a truncated version of gD (gDt) (BAV3.E3gDt), or with E3-deleted BAV-3 (BAV3.E3d; control), were challenged with BHV-1 strain 108. Vaccination with BAV3.E3gD or BAV3.E3gDt induced gD-specific antibody responses in serum and nasal secretions, and primed calves for gD-specific lymphoproliferative responses. In addition, all calves developed complement-independent neutralizing antibodies against BHV-1. Protection against viral challenge was observed in calves vaccinated with recombinant BAV3.E3gD or BAV3.E3gDt as shown by a significant reduction in body temperature and clinical disease, and a partial reduction in the amount and duration of virus excretion in nasal secretions. These results indicate that replication-competent BAV-3-based vectors can induce protective immune responses in calves (the natural host) that have pre-existing BAV-3-specific antibodies.
BabiukL. A.,
L’ltalienJ.,
van Drunen Littel-van den HurkS.,
ZambT.,
LawmanM. J. P.,
HughesG.,
GiffordG. A.1987; Protection of cattle from bovine herpesvirus type-1 (BHV-1) infection by immunization with individual viral glycoproteins. Virology 159:57–66
BabuikL. A.,
van Drunen Littel-van den HurkS.,
TikooS. K.,
LewisP. J.,
LiangX.1996; Novel viral vaccines for livestock. Veterinary Immunology and Immunopathology 54:355–363
CallebautP.,
EnjuanesL.,
PensaertM.1996; An adenovirus recombinant expressing the spike glycoprotein of porcine respiratory coronavirus is immunogenic in swine. Journal of General Virology 77:309–313
CzerkinskyC. C.,
NilssonL. A.,
NygrenH.,
OuchterlonyO.,
TarkowskiA.1983; A solid phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. Journal of Immunological Methods 65:109
IsraelB. A.,
HerberR.,
GaoY.,
LetchworthG. J.III1992; Induction of a mucosal barrier to bovine herpesvirus 1 replication in cattle. Virology 188:256–264
MittalS. K.,
PrevecL.,
GrahamF. L.,
BabiukL. A.1995; Development of bovine adenovirus type 3-based expression vector. Journal of General Virology 76:93–102
MittalS. K.,
PappZ.,
TikooS. K.,
Baca-EstradaM. E.,
YooD.,
BenkoM.,
BabiukL. A.1996; Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Virology 222:299–309
PappZ.,
MiddletonD. M.,
MittalS. K.,
BabiukL. A.,
Baca-EstradaM. E.1997; Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection. Journal of General Virology 78:2933–2943
PappZ.,
BabiukL. A.,
Baca-EstradaM. E.1998; Induction of immunity in respiratory tract and protection from bovine herpesvirus type 1 infection by different routes of immunization with recombinant adenovirus. Viral Immunology 11:79–91
PrevecL.,
SchneiderM.,
RosenthalK. L.,
BelbeckL. W.,
DerbyshireJ. B.,
GrahamF. L.1989; Use of human adenovirus-based vectors for antigen expression in animals. JournalofGeneral Virology 70:429–434
ReddyP. S.,
IdamakantiN.,
ZakhartchoukA. N.,
BaxiM. K.,
LeeJ. B.,
PyneC.,
BabiukL. A.,
TikooS. K.1998; genome organization and the transcription map of bovine adenovirus type 3. Journal of Virology 72:1394–1402
RosenthalK. L.,
CopelandK. F. T.,
GallichanW. S.1996; Recombinant adenoviruses as vectors for mucosal immunity. In Mucosal Vaccines pp 147–158 Edited by
KlyonoH.,
OgraP. L.,
McGheeJ. R.
San Diego: Academic Press;
RouseB. T.,
BabiukL. A.1974; Host responses to infectious bovine rhinotracheitis. III. Isolation and immunological activities of bovine lymphocytes. Journal of Immunology 113:1391–1398
TikooS. K.,
FitzpatrickD.,
BabiukL. A.,
ZambT. J.1990; Molecular cloning, sequencing and expression of functional bovine herpesvirus-1 glycoprotein gIV in transfected bovine cells. Journal of Virology 64:5132–5142
TikooS. K.,
ZambT. J.,
BabiukL. A.1993; Analysis of bovine herpesvirus-1 glycoprotein gIV truncations and deletions expressed by recombinant vaccinia viruses. Journal of Virology 67:2103–2109
TorresJ. M.,
AlonsoC.,
OrtegaA.,
MittalS.,
GrahamF.,
EnjuanesL.1996; Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. Journal of Virology 70:3770–3780
Van Drunen Littel-van den HurkS.,
ParkerM. D.,
MassieB.,
van den HurkJ.,
HarlandR.,
BabiukL. A.,
ZambT. J.1993; Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein gIV. Vaccine 11:25–35
Van Drunen Littel-van den HurkS.,
van DonkersgoedJ.,
KowalskiJ.,
van den HurkJ. V.,
HarlandR.,
BabiukL. A.,
ZambT. J.1994; A subunit gIV vaccine produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle. Vaccine 12:1295–1302
Van Drunen Littel-van den HurkS.,
TikooS. K.,
van den HurkJ. V.,
BabiukL. A.,
van DonkersgoedJ.1997; Protective immunity in cattle following vaccination with conventional and marker bovine herpesvirus-1 (BHV-1) vaccines. Vaccine 15:36–44
YatesW. D. G.1982; A review of infectious bovine rhinotracheitis, shipping fever pneumonia and viral bacterial synergism in respiratory diseases of cattle. Canadian Journal of Comparative Medicine 46:225–263
ZakhartchoukA. N.,
ReddyP. S.,
BaxiM.,
Baca-EstradaM. E.,
MehtaliM.,
BabiukL. A.,
TikooS. K.1998; Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD. Virology 250:220–229
ZuX.,
LetchworthG. J.1996; Mucosal and systemic immunity to bovine herpesvirus-1 glycoprotein D confer resistance to viral replication and latency in cattle. Vaccine 14:61–69